Articles about Serum Institute of India

India is likely to get its first vaccine for dengue soon as the Indian Council of Medical Research (ICMR) is all set to submit its clinical trial protocol to the country's drug regulator CDSCO by June.

The Centre on Saturday announced that private vaccination centers can charge a service fee of up to Rs. 150 in addition to the cost of the precautionary dose of the COVID-19 vaccine from beneficiaries.

The Drugs Controller General of India (DCGI) has granted Emergency Use Authorisation to the coronavirus vaccine Covovax for restricted emergency use in children above the age of 12.

The subject expert committee (SEC) of India's drug regulatory authority Central Drugs Standard Control Organization (CDSCO) has recommended phase-3 clinical trials of Covovax as a booster dose against COVID-19 in adults, Mint reported.

Billions need to be vaccinated at a faster rate to reach the end of the COVID-19 pandemic, said Adar Poonawalla, CEO of the Serum Institute of India (SII), which manufactures the COVID-19 vaccine Covishield.

The Serum Institute of India is looking to launch a COVID-19 vaccine for children in six months, SII CEO Adar Poonawalla said Tuesday.

Seven COVID-19 vaccines are safe and stimulate a strong immune response when used as a booster jab to those who have already vaccinated, a study published in The Lancet said.

The COVID-19 vaccine manufacturers in India are reportedly waiting for "more data" on the new coronavirus variant, Omicron, to assess the efficacy of their vaccines.

The Serum Institute of India (SII) has received the approval to conduct trials of the Novavax COVID-19 vaccine in children aged between seven and 11 years.

Serum Institute of India Chairman Cyrus Poonawalla on Friday said that taking a third or booster dose of Covishield, the coronavirus vaccine manufactured by his firm was desirable.

The European Medicines Agency (EMA) said it has not received any application for the authorization of the coronavirus vaccine Covishield.

The Serum Institute of India (SII) will begin producing the Russian COVID-19 vaccine, Sputnik V, from September, the Russian Direct Investment Fund (RDIF) announced today.

A Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organization (CDSCO) has denied permission to Pune-based Serum Institute of India (SII) for conducting clinical trials of its second COVID-19 vaccine, Covovax, in children.

The Serum Institute of India (SII) has not yet applied for the approval of its coronavirus vaccine Covishield in the "Green Pass" issued by the European Union, according to a statement from the EU.

The Serum Institute of India (SII) will soon apply for regulatory approval to conduct clinical trials of Covovax on children in India.

The WHO is urgently trying to work with AstraZeneca, Serum Institute of India (SII) as well as the Indian government to restart shipments of COVID-19 vaccines to countries, a senior official at the UN health agency said.

The Serum Institute of India (SII) is looking to launch the COVID-19 vaccine developed by the United States firm Novavax in India by September.

The Serum Institute of India has requested the Indian government to provide it indemnity from liability in connection with its COVID-19 vaccines, company sources cited by NDTV and The Hindu say.

The AAP on Friday alleged that the Centre is creating artificial scarcity of COVID-19 vaccines to benefit Bharat Biotech and Serum Institute of India, a charge termed by the Delhi BJP as unfounded.

A government expert panel has reportedly recommended raising the time gap between two doses of the COVID-19 vaccine Covishield to 12-16 weeks.

The Serum Institute of India and Bharat Biotech, the two companies India has entrusted to make its coronavirus vaccines, have both submitted their productions plans for the coming four months to the Indian government.

The United States is considering the production of Johnson & Johnson's COVID-19 vaccine in India along with ways to help manufacturers like the Serum Institute of India (SII) to boost production, Daniel B Smith, Charge d'Affaires of the US Embassy, said on Tuesday.

Maharashtra Health Minister Rajesh Tope on Monday urged Serum Institute of India Chief Executive Officer Adar Poonawalla to give priority to the state in providing its anti-coronavirus vaccine, Covishield, as the government was ready to purchase doses from the Pune-based company.

The Health Ministry on Monday said that a 100 percent advance of Rs. 1732.50 crore was released to the Serum Institute of India on April 28 for 11 crore doses of Covishield vaccine during May, June, and July.

Serum Institute of India CEO Adar Poonawalla has revealed that his decision to fly to London when India is facing a COVID-19 second wave was largely due to the threats he had been facing.

Adar Poonawalla, the CEO of the Serum Institute of India (SII), on Wednesday announced that the price of the COVID-19 vaccine Covishield was being reduced from Rs. 400 to Rs. 300 for states.

The central government has asked the Serum Institute of India (SII) and Bharat Biotech to reduce the prices of their COVID-19 vaccines, PTI reported on Monday.

Serum Institute of India (SII) will sell Covishield at Rs. 400 per shot to states and at Rs. 600 to private hospitals, the Pune-based vaccine manufacturer said today.

The Biden administration has conveyed to New Delhi that it understands India's pharmaceutical requirements and promised to give the matter due consideration, observing that the current difficulty in the export of critical raw materials needed to manufacture COVID-19 vaccines is mainly due to an Act that forces American companies to prioritize domestic consumption.

Pune-based Serum Institute of India (SII) has fully refunded South Africa for 500,000 undelivered doses of the coronavirus vaccine, reports PTI.

Serum Institute of India (SII), the manufacturer of the coronavirus vaccine Covishield, has been served a legal notice by the drug maker AstraZeneca over delays in vaccine supply, the company's CEO Adar Poonawalla confirmed in an interview earlier this week.

The efficacy of the COVID-19 vaccine Covishield could increase to 90% if the two doses are given 2.5-3 months apart, Serum Institute of India CEO Adar Poonawalla said Monday.

Serum Institute of India CEO Adar Poonawalla today said that his company hopes to launch its second coronavirus vaccine by September this year.

Facing a sudden spike in coronavirus cases, India has halted the export of the AstraZeneca vaccine for now, Reuters reported quoting two sources. Millions of doses of the vaccine are being manufactured by the Pune-based Serum Institute of India (SII), the world's biggest vaccine-maker.

The Serum Institute of India (SII) will reportedly be delaying COVID-19 vaccine supplies to Brazil, Saudi Arabia, and Morocco amid criticism that India is not vaccinating enough people at home.

The Delhi High Court on Thursday pulled up the central government over restricted COVID-19 vaccinations in India, even as vaccine exports to other nations continue.

British-Swedish pharmaceutical giant AstraZeneca and US pharmaceutical major Novavax have told lawmakers that they are ready to scale up their production of COVID-19 vaccines in partnership with the Serum Institute of India.

The Madras High Court on Friday issued a notice to the central government, among others, in a case pertaining to the alleged adverse reaction to the COVID-19 vaccine Covishield.

Sri Lanka will purchase ten million doses of Oxford-AstraZeneca's Covishield vaccine from India, officials have said.

According to a new Oxford University study, the first dose of the two-dose Oxford/AstraZeneca vaccine can cut coronavirus transmissions by around 67 percent and therefore, have a substantial effect on controlling the spread.